FDA completed mid-cycle review of INO-3107, and Inovio Pharmaceuticals announced the appointment of EY as its independent registered public accounting firm.
3 reports, 3 independent
Updated Nov 1
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA completed mid-cycle review of INO-3107, and Inovio Pharmaceuticals announced the appointment of EY as its independent registered public accounting firm.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Inovio's Voceryq received accelerated approval from the FDA.1 source
FDA grants accelerated approval to INO-3107 following mid-cycle review.1 source
Inovio received mid-cycle review from the FDA for INO-3107 and appointed EY as its accounting firm.1 source
Keep exploring
The entities involved
- FDA
-
Inovio Pharmaceuticals
American biotechnology company
Nothing else this week.
- Ernst & Young LLP
-
Securities and Exchange Commission
government agency of the Philippines